Financhill
Back

Intellia Therapeutics Quote, Financials, Valuation and Earnings

Introducing The Great $2 AI Moonshot

Open your free presentation now
Sell
16

NTLA
Intellia Therapeutics

Last Price:
31.61
Seasonality Move:
10.55%

7 Day Trial

ALL ACCESS PASS

$ 7

Wall Street Caliber A.I. for the "Little Guy"

Get the full story here

Intellia Therapeutics Price Quote

$31.61
+0.01 (+-0.47%)
(Updated: September 30, 2023 at 5:52 AM ET)

Intellia Therapeutics Key Stats

Sell
16
Intellia Therapeutics (NTLA) is a Sell

Day range:
$31.39 - $32.47
52-week range:
$31.13 - $63.12
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
49.64
P/B ratio:
2.53%

Volume:
600.5K
Avg. volume:
751.6K
1-year change:
-42.85%
Market cap:
$2.8B
Revenue:
$52.1M
EPS:
$-5.46

How Much Does Intellia Therapeutics Make?

Is Intellia Therapeutics Growing As A Company?

  • What Is Intellia Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.03%
  • What Is Intellia Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Intellia Therapeutics Stock Price Performance

What Is Intellia Therapeutics 52-Week High & Low?

Intellia Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Intellia Therapeutics?

Is Intellia Therapeutics Cash Flow Positive?

  • What Is NTLA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$368M
  • What Is Intellia Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $534.5M
  • What Is Intellia Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$139.3M

Intellia Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    NTLA return on invested capital is -43.29%
  • What Is Intellia Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -35.12%
  • What Is NTLA Return On Equity?
    ROE is a measure of profitability and is -43.29%

Intellia Therapeutics Earnings Date & Stock Price

Intellia Therapeutics Competitors

  • Who Are Intellia Therapeutics's Competitors?
    Below is a list of companies who compete with Intellia Therapeutics or are related in some way:
    • Perspective Therapeutics Inc (CATX)
    • Electromed Inc (ELMD)
    • Navidea Biopharmaceuticals Inc (NAVB)
    • Pacific Biosciences of California Inc (PACB)
    • Xtant Medical Holdings Inc (XTNT)

Intellia Therapeutics Dividend Yield

Data Unavailable

Intellia Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -5.43%
Revenue: -3.11% 20.14%

Analyst Recommendations

Buy Recommendations: 17
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 85.08
Upside from Last Price: 169.24%

Major Shareholders

  • How many NTLA shares are owned by institutional investors?
    112.9M NTLA shares are owned by institutional investors
  • How many NTLA shares are owned by insiders?
    2.5M NTLA shares are owned by insiders